查看购物车
  • Traditional Chinese
  • English
封面
市场调查报告书
商品编码
1808940

额颞叶失智症市场，按药物类别、按疾病适应症、按配销通路、按国家和地区 - 2025 年至 2032 年全球行业分析、市场规模、市场份额和预测

Frontotemporal Dementia Market, By Drug Class, By Disease Indication, By Distribution Channel, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032
出版日期: | 出版商: AnalystView Market Insights | 英文 304 Pages | 商品交期: 2-3个工作天内

价格
简介目录

2024 年额颞叶失智症市场规模价值 2.4518 亿美元，2025 年至 2032 年的复合年增长率为 7.20%。

额颞叶疾病是一种导致大脑额叶或颞叶神经细胞退化的神经系统疾病。这类疾病包括失智症、进行性核上性麻痹和原发性进行性失语症，会对行为、语言、运动和个性产生重大影响，限制人们执行日常任务的能力。额颞叶疾病，也称为额颞叶变性，是一种主要影响额叶和颞叶的神经系统疾病。这种疾病的特征是神经细胞进行性丧失和痴呆症的发生。

额颞叶失智症市场-市场动态

神经退化性疾病盛行率上升推动市场成长

神经退化性疾病的盛行率日益上升，尤其是在老化和高遗传风险族群中，是额颞叶失智症 (FTD) 市场的主要驱动力。 FTD 是早发性失智症最常见的原因之一，随着认知度、诊断和报告水平的提高，全球发现了越来越多的病例。随着预期寿命的延长和神经系统筛检的普及，对有效 FTD 治疗的需求也随之增长。这一趋势正鼓励製药和生技公司投资新型疗法，例如基因疗法和抗 tau 蛋白药物。此外，医疗保健系统将早期发现和介入放在首位，这推动了市场的成长。全球神经退化性疾病的负担使得 FTD 仍然是尚未满足医疗需求的关键领域。

额颞叶失智症市场－关键洞察

根据我们的研究分析师的分析，预测期内（2025-2032 年）全球市场预计年复合成长率约为 7.20%

根据药物类别的细分，预计抗忧郁药物将在 2025 年占据最大的市场份额。

根据疾病适应症细分，额颞叶失智症是2025年最常见的疾病适应症。

2025年，北美将成为收入最高的地区。

额颞叶失智症市场-細項分析：

全球额颞叶失智症市场根据药物类别、疾病适应症、配销通路和地区进行细分。

根据药物类别，市场分为五类：认知增强剂、抗忧郁药、抗精神病药、中枢神经兴奋剂和其他药物类别。预计抗忧郁药物将在预测期内带来丰厚的市场机会。抗忧郁药物主要用于治疗忧郁症和其他疾病，例如心境恶劣障碍、强迫症 (OCD)、焦虑症、神经性疼痛、饮食失调和慢性疼痛。医生经常开立各种类型的抗忧郁药物来改善患者的健康状况。选择性血清素再摄取抑制剂 (SSRI) 已被证明对治疗额颞叶疾病有益。

根据疾病适应症，市场分为三类：额颞叶失智症、运动障碍、原发性进行性失语症。额颞叶失智症在2025年占据额颞叶失智症市场的最大份额，预计在2026-2030年的预测期内将进一步成长。额颞叶失智症是一组罕见的脑部疾病，主要影响额叶和颞叶，导致人格、语言和行为的改变。儘管额颞叶失智症经常被误诊为阿兹海默症，但其发病年龄通常较年轻，介于40至65岁之间。

额颞叶失智症市场—地理洞察

北美凭藉其先进的医疗基础设施、高昂的医疗支出以及广泛的研发活动，占据市场主导地位。尤其是美国，由于其庞大的老年人口和大型製药公司的存在，在区域市场中占据主导地位。该地区重视早期诊断和干预，并开展了广泛的宣传活动，巩固了其市场领导地位。预计北美市场在预测期内将维持稳定的复合年增长率。

预计亚太地区将在预测期内经历最快速的成长。该地区庞大的老龄人口，尤其是在中国、日本和印度，推动了对痴呆症治疗的需求。医疗保健投资的增加和先进技术的采用有助于推动市场成长。该地区各国政府正在积极推动宣传活动，并资助研究项目，以应对日益加重的痴呆症负担。预计亚太市场将以快速的复合年增长率成长，这反映了该地区对改善医疗保健基础设施和增加痴呆症治疗可及性的重视。

额颞叶失智症市场-竞争格局：

额颞叶失智症 (FTD) 市场瞬息万变，製药巨头和创新生物技术公司竞相开发针对这种复杂神经退化性疾病的有效疗法。包括 Transposon Therapeutics、阿斯特捷利康公司、Alector Inc.、辉瑞公司和 Denali Therapeutics Inc. 在内的领先公司正在进行针对 tau 蛋白积聚和前颗粒蛋白缺乏症的疾病修饰疗法的高级研究。孤儿药资格认定、产学合作的不断加强以及精准诊断领域投资的不断增加，都在推动市场向前发展。

最新动态：

2024年7月，美国食品药物管理局（FDA）批准Alpha Cognition的口服疗法ZUNVEYL在美国用于治疗阿兹海默症。这种新型药物具有独特的双重作用机制，可改善认知功能，同时比现有疗法具有更好的耐受性。 ZUNVEYL是阿兹海默症护理领域的一项有希望的进展，旨在满足患者和照护者尚未满足的需求。

目录

第一章：额颞叶失智症市场概述

  • 研究范围
  • 市场估计年限

第二章：执行摘要

  • 市场片段
    • 额颞叶失智症市场片段（依药物类别）
    • 额颞叶失智症市场片段（依疾病适应症）
    • 额颞叶失智症市场片段（依配销通路）
    • 额颞叶失智症市场（依国家）
    • 额颞叶失智症市场片段（按地区）
  • 竞争洞察

第三章：额颞叶失智症主要市场趋势

  • 额颞叶失智症市场驱动因素
    • 市场驱动因素的影响分析
  • 额颞叶失智症市场限制
    • 市场限制的影响分析
  • 额颞叶失智症市场机会
  • 额颞叶失智症市场未来趋势

第四章：额颞叶失智症产业研究

  • PEST分析
  • 波特五力分析
  • 成长前景图
  • 规范架构分析

第五章：额颞叶失智症市场：地缘政治紧张局势升级的影响

  • COVID-19 疫情的影响
  • 俄乌战争的影响
  • 中东衝突的影响

第六章：额颞叶失智症市场格局

  • 2024年额颞叶失智症市场占有率分析
  • 按主要製造商分類的细分数据
    • 成熟玩家分析
    • 新兴企业分析

第七章：额颞叶失智症市场－依药物类别

  • 概述
    • 按药物类别分類的细分市场份额分析
    • 认知增强剂
    • 抗忧郁药
    • 抗精神病药物
    • 中枢神经兴奋剂
    • 其他药物类别

第 8 章：额颞叶失智症市场 - 按疾病适应症

  • 概述
    • 按疾病适应症分類的细分份额分析
    • 额颞叶失智症
    • 运动障碍
    • 原发性进行性失语症

第九章：额颞叶失智症市场－按配销通路

  • 概述
    • 按配销通路分類的细分市场份额分析
    • 医院药房
    • 网路药局
    • 零售药局

第十章：额颞叶失智症市场－依地区划分

  • 介绍
    • 按地区分類的细分市场占有率分析
  • 北美洲
    • 概述
    • 北美额颞叶失智症主要製造商
    • 北美市场规模及预测（按国家/地区）
    • 北美市场规模及预测（依药品类别）
    • 北美市场规模及预测（依疾病类型划分）
    • 北美市场规模及预测（按配销通路）
    • 我们
    • 加拿大
  • 欧洲
    • 概述
    • 欧洲额颞叶失智症主要製造商
    • 欧洲市场规模及预测（按国家/地区）
    • 欧洲市场规模及预测（依药品类别）
    • 欧洲市场规模及预测（依疾病类型划分）
    • 欧洲市场规模及预测（按配销通路）
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 荷兰
    • 瑞典
    • 俄罗斯
    • 波兰
    • 欧洲其他地区
  • 亚太地区 (APAC)
    • 概述
    • 亚太地区额颞叶失智症主要製造商
    • 亚太地区市场规模及预测（依国家）
    • 亚太地区市场规模及预测（依药品类别）
    • 亚太地区市场规模及预测（依疾病类型划分）
    • 亚太地区市场规模及预测（按配销通路）
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲
    • 印尼
    • 泰国
    • 菲律宾
    • 亚太地区其他地区
  • 拉丁美洲（LATAM）
    • 概述
    • 拉丁美洲额颞叶失智症主要製造商
    • 拉丁美洲市场规模及预测（按国家/地区）
    • 拉丁美洲市场规模及预测（依药品类别）
    • 拉丁美洲市场规模及预测（依疾病类型划分）
    • 拉丁美洲市场规模及预测（按配销通路）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥伦比亚
    • 拉丁美洲其他地区
  • 中东和非洲（MEA）
    • 概述
    • 中东和非洲额颞叶失智症主要製造商
    • MEA 市场规模及预测（依国家/地区）
    • MEA 市场规模及预测（依药物类别）
    • MEA 市场规模及预测（依疾病类型划分）
    • MEA 市场规模及预测（依配销通路）
    • 沙乌地阿拉伯
    • 阿联酋
    • 以色列
    • 土耳其
    • 阿尔及利亚
    • 埃及
    • MEA 其余地区

第 11 章：额颞叶失智症产业主要供应商分析

  • 竞争基准化分析
    • Competitive Dashboard
    • Competitive Positioning
  • 公司简介
    • Transposon Therapeutics
    • AstraZeneca plc
    • Alector Inc.
    • Pfizer Inc.
    • Denali Therapeutics Inc.
    • Johnson & Johnson Services Inc.
    • Prevail Therapeutics
    • Wave Life Sciences
    • GlaxoSmithKline plc
    • TauRx Pharmaceuticals Ltd.
    • Others

第 12 章：360 度分析师视角

第 13 章：附录

  • 研究方法
  • 参考
  • 缩写
  • 免责声明
  • 联络我们
简介目录
Product Code: ANV5569

Frontotemporal Dementia Market size was valued at US$ 245.18 Million in 2024, expanding at a CAGR of 7.20% from 2025 to 2032.

Frontotemporal diseases are neurological conditions that cause nerve cell degeneration in the brain's frontal or temporal lobes. This condition, which includes dementia, progressive supranuclear palsy, and primary progressive aphasia, has a significant impact on behavior, language, movement, and personality, limiting people's ability to carry out daily tasks. Frontotemporal disorders, also known as frontotemporal lobar degeneration, are neurological conditions that primarily affect the frontal and temporal lobes. This condition is defined by the progressive loss of nerve cells and the onset of dementia.

Frontotemporal Dementia Market- Market Dynamics

Rising Prevalence of Neurodegenerative Disorders Drives Market Growth

The growing prevalence of neurodegenerative disorders, particularly in the aging and genetically at-risk populations, is a major driver of the frontotemporal dementia (FTD) market. FTD is one of the most common causes of early-onset dementia, and more cases are being discovered around the world as awareness, diagnostics, and reporting improve. As life expectancy rises and neurological screening becomes more widely available, the demand for effective FTD treatments has increased. This trend is encouraging pharmaceutical and biotech companies to invest in new therapeutics, such as gene therapies and anti-tau drugs. In addition, healthcare systems are prioritizing early detection and intervention, which is driving market growth. The global burden of neurodegenerative diseases ensures that FTD remains a critical area of unmet medical need.

Frontotemporal Dementia Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 7.20% over the forecast period (2025-2032)

According to the segmentation of drug classes, antidepressants were expected to hold the largest market share in 2025.

According to segmentation of disease indications, frontotemporal dementia was the most common disease indication in 2025.

In 2025, North America ranked as the top revenue-generating region.

Frontotemporal Dementia Market- Segmentation Analysis:

The Global Frontotemporal Dementia Market is segmented on the basis of Drug Class, Disease Indication, Distribution Channel, and Region.

The market is separated into five groups according to the drug class: Cognitive Enhancers, Antidepressants, Antipsychotics, CNS Stimulants and Other Drug Classes. Antidepressants are expected to provide a lucrative opportunity during the forecast period. Antidepressant medications are primarily used to treat depressive disorders and other conditions such as dysthymia, obsessive-compulsive disorder (OCD), anxiety disorders, neuropathic pain, eating disorders, and chronic pain. Physicians frequently prescribe various types of antidepressants to improve patient health. Selective serotonin reuptake inhibitors (SSRIs) have proven beneficial in treating frontotemporal disorders.

The market is divided into three categories based on Disease Indication: Frontotemporal Dementia, Movement Disorders, and Primary Progressive Aphasia. Frontotemporal Dementia hold the largest market share in the Frontotemporal Dementia Market in 2025, and it is expected to grow further during the forecast period 2026-2030. Frontotemporal dementia is a collection of rare brain disorders that primarily affect the frontal and temporal lobes, resulting in changes in personality, language, and behavior. Despite frequently being misdiagnosed as Alzheimer's disease, frontotemporal dementia usually appears at a younger age, between 40 and 65.

Frontotemporal Dementia Market- Geographical Insights

North America dominates the market, owing to its advanced healthcare infrastructure, high healthcare expenditure, and extensive R&D activities. The United States, in particular, dominates the regional market due to its large elderly population and the presence of major pharmaceutical companies. The region's emphasis on early diagnosis and intervention, combined with extensive awareness campaigns, adds to its market leadership. The North American market is expected to grow at a steady CAGR over the forecast period.

The Asia Pacific region is expected to experience the most rapid growth during the forecast period. The region's large aging population, particularly in China, Japan, and India, drives up demand for dementia treatments. Increased healthcare investment and the adoption of advanced technologies help to drive market growth. The region's governments are actively promoting awareness campaigns and funding research initiatives to address the growing burden of dementia. The Asia Pacific market is expected to grow at a rapid CAGR, reflecting the region's emphasis on improving healthcare infrastructure and increasing access to dementia treatment.

Frontotemporal Dementia Market- Competitive Landscape:

The frontotemporal dementia (FTD) market is rapidly changing, with pharmaceutical giants and innovative biotech firms competing to develop effective treatments for this complex neurodegenerative condition. Leading companies, including Transposon Therapeutics, AstraZeneca plc, Alector Inc., Pfizer Inc., and Denali Therapeutics Inc., are conducting advanced research on disease-modifying treatments for tau protein accumulation and progranulin deficiencies. Orphan drug designations, growing collaborations between industry and academia, and increased investment in precision diagnostics are all driving the market forward.

Recent Developments:

In July 2024, The FDA has approved Alpha Cognition's oral therapy, ZUNVEYL, for the treatment of Alzheimer's disease in the US. This novel medication has a unique dual mechanism of action that improves cognitive function while providing better tolerability than existing treatments. ZUNVEYL is a promising advancement in Alzheimer's care that seeks to meet the unmet needs of patients and caregivers.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL FRONTOTEMPORAL DEMENTIA MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Transposon Therapeutics
  • AstraZeneca plc
  • Alector Inc.
  • Pfizer Inc.
  • Denali Therapeutics Inc.
  • Johnson & Johnson Services Inc.
  • Prevail Therapeutics
  • Wave Life Sciences
  • GlaxoSmithKline plc
  • TauRx Pharmaceuticals Ltd.
  • Others

GLOBAL FRONTOTEMPORAL DEMENTIA MARKET, BY DRUG CLASS- MARKET ANALYSIS, 2019 - 2032

  • Cognitive Enhancers
  • Antidepressants
  • Antipsychotics
  • CNS Stimulants
  • Other Drug Classes

GLOBAL FRONTOTEMPORAL DEMENTIA MARKET, BY DISEASE INDICATION- MARKET ANALYSIS, 2019 - 2032

  • Frontotemporal Dementia
  • Movement Disorders
  • Primary Progressive Aphasia

GLOBAL FRONTOTEMPORAL DEMENTIA MARKET, BY DISTRIBUTION CHANNEL- MARKET ANALYSIS, 2019 - 2032

  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies

GLOBAL FRONTOTEMPORAL DEMENTIA MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
  • Sweden
  • Russia
  • Poland
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Frontotemporal Dementia Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Frontotemporal Dementia Market Snippet by Drug Class
    • 2.1.2. Frontotemporal Dementia Market Snippet by Disease Indication
    • 2.1.3. Frontotemporal Dementia Market Snippet by Distribution Channel
    • 2.1.4. Frontotemporal Dementia Market Snippet by Country
    • 2.1.5. Frontotemporal Dementia Market Snippet by Region
  • 2.2. Competitive Insights

3. Frontotemporal Dementia Key Market Trends

  • 3.1. Frontotemporal Dementia Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Frontotemporal Dementia Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Frontotemporal Dementia Market Opportunities
  • 3.4. Frontotemporal Dementia Market Future Trends

4. Frontotemporal Dementia Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Frontotemporal Dementia Market: Impact of Escalating Geopolitical Tensions

  • 5.1. Impact of COVID-19 Pandemic
  • 5.2. Impact of Russia-Ukraine War
  • 5.3. Impact of Middle East Conflicts

6. Frontotemporal Dementia Market Landscape

  • 6.1. Frontotemporal Dementia Market Share Analysis, 2024
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Frontotemporal Dementia Market - By Drug Class

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Drug Class, 2024 & 2032 (%)
    • 7.1.2. Cognitive Enhancers
    • 7.1.3. Antidepressants
    • 7.1.4. Antipsychotics
    • 7.1.5. CNS Stimulants
    • 7.1.6. Other Drug Classes

8. Frontotemporal Dementia Market - By Disease Indication

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Disease Indication, 2024 & 2032 (%)
    • 8.1.2. Frontotemporal Dementia
    • 8.1.3. Movement Disorders
    • 8.1.4. Primary Progressive Aphasia

9. Frontotemporal Dementia Market - By Distribution Channel

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Distribution Channel, 2024 & 2032 (%)
    • 9.1.2. Hospital Pharmacies
    • 9.1.3. Online Pharmacies
    • 9.1.4. Retail Pharmacies

10. Frontotemporal Dementia Market- By Geography

  • 10.1. Introduction
    • 10.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
  • 10.2. North America
    • 10.2.1. Overview
    • 10.2.2. Frontotemporal Dementia Key Manufacturers in North America
    • 10.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.2.4. North America Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.2.5. North America Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
    • 10.2.6. North America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.2.7. U.S.
      • 10.2.7.1. Overview
      • 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.7.3. U.S. Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.2.7.4. U.S. Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 10.2.7.5. U.S. Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.2.8. Canada
      • 10.2.8.1. Overview
      • 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.8.3. Canada Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.2.8.4. Canada Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 10.2.8.5. Canada Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.3. Europe
    • 10.3.1. Overview
    • 10.3.2. Frontotemporal Dementia Key Manufacturers in Europe
    • 10.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.3.4. Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.3.5. Europe Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
    • 10.3.6. Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.7. Germany
      • 10.3.7.1. Overview
      • 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.7.3. Germany Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.3.7.4. Germany Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 10.3.7.5. Germany Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.8. UK
      • 10.3.8.1. Overview
      • 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.8.3. UK Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.3.8.4. UK Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 10.3.8.5. UK Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.9. France
      • 10.3.9.1. Overview
      • 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.9.3. France Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.3.9.4. France Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 10.3.9.5. France Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.10. Italy
      • 10.3.10.1. Overview
      • 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.10.3. Italy Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.3.10.4. Italy Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 10.3.10.5. Italy Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.11. Spain
      • 10.3.11.1. Overview
      • 10.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.11.3. Spain Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.3.11.4. Spain Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 10.3.11.5. Spain Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.12. The Netherlands
      • 10.3.12.1. Overview
      • 10.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.12.3. The Netherlands Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.3.12.4. The Netherlands Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 10.3.12.5. The Netherlands Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.13. Sweden
      • 10.3.13.1. Overview
      • 10.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.13.3. Sweden Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.3.13.4. Sweden Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 10.3.13.5. Sweden Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.14. Russia
      • 10.3.14.1. Overview
      • 10.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.14.3. Russia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.3.14.4. Russia Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 10.3.14.5. Russia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.15. Poland
      • 10.3.15.1. Overview
      • 10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.15.3. Poland Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.3.15.4. Poland Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 10.3.15.5. Poland Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.16. Rest of Europe
      • 10.3.16.1. Overview
      • 10.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.16.3. Rest of the Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.3.16.4. Rest of the Europe Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 10.3.16.5. Rest of the Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.4. Asia Pacific (APAC)
    • 10.4.1. Overview
    • 10.4.2. Frontotemporal Dementia Key Manufacturers in Asia Pacific
    • 10.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.4.4. APAC Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.4.5. APAC Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
    • 10.4.6. APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.7. China
      • 10.4.7.1. Overview
      • 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.7.3. China Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.4.7.4. China Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 10.4.7.5. China Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.8. India
      • 10.4.8.1. Overview
      • 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.8.3. India Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.4.8.4. India Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 10.4.8.5. India Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.9. Japan
      • 10.4.9.1. Overview
      • 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.9.3. Japan Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.4.9.4. Japan Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 10.4.9.5. Japan Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.10. South Korea
      • 10.4.10.1. Overview
      • 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.10.3. South Korea Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.4.10.4. South Korea Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 10.4.10.5. South Korea Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.11. Australia
      • 10.4.11.1. Overview
      • 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.11.3. Australia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.4.11.4. Australia Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 10.4.11.5. Australia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.12. Indonesia
      • 10.4.12.1. Overview
      • 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.12.3. Indonesia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.4.12.4. Indonesia Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 10.4.12.5. Indonesia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.13. Thailand
      • 10.4.13.1. Overview
      • 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.13.3. Thailand Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.4.13.4. Thailand Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 10.4.13.5. Thailand Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.14. Philippines
      • 10.4.14.1. Overview
      • 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.14.3. Philippines Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.4.14.4. Philippines Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 10.4.14.5. Philippines Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.15. Rest of APAC
      • 10.4.15.1. Overview
      • 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.15.3. Rest of APAC Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.4.15.4. Rest of APAC Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 10.4.15.5. Rest of APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.5. Latin America (LATAM)
    • 10.5.1. Overview
    • 10.5.2. Frontotemporal Dementia Key Manufacturers in Latin America
    • 10.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.5.4. LATAM Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.5.5. LATAM Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
    • 10.5.6. LATAM Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.5.7. Brazil
      • 10.5.7.1. Overview
      • 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.7.3. Brazil Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.5.7.4. Brazil Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 10.5.7.5. Brazil Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.5.8. Mexico
      • 10.5.8.1. Overview
      • 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.8.3. Mexico Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.5.8.4. Mexico Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 10.5.8.5. Mexico Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.5.9. Argentina
      • 10.5.9.1. Overview
      • 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.9.3. Argentina Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.5.9.4. Argentina Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 10.5.9.5. Argentina Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.5.10. Colombia
      • 10.5.10.1. Overview
      • 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.10.3. Colombia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.5.10.4. Colombia Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 10.5.10.5. Colombia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.5.11. Rest of LATAM
      • 10.5.11.1. Overview
      • 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.11.3. Rest of LATAM Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.5.11.4. Rest of LATAM Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 10.5.11.5. Rest of LATAM Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.6. Middle East and Africa (MEA)
    • 10.6.1. Overview
    • 10.6.2. Frontotemporal Dementia Key Manufacturers in Middle East and Africa
    • 10.6.3. MEA Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.6.4. MEA Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.6.5. MEA Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
    • 10.6.6. MEA Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.7. Saudi Arabia
      • 10.6.7.1. Overview
      • 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.7.3. Saudi Arabia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.6.7.4. Saudi Arabia Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 10.6.7.5. Saudi Arabia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.8. UAE
      • 10.6.8.1. Overview
      • 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.8.3. UAE Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.6.8.4. UAE Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 10.6.8.5. UAE Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.9. Israel
      • 10.6.9.1. Overview
      • 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.9.3. Israel Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.6.9.4. Israel Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 10.6.9.5. Israel Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.10. Turkey
      • 10.6.10.1. Overview
      • 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.10.3. Turkey Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.6.10.4. Turkey Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 10.6.10.5. Turkey Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.11. Algeria
      • 10.6.11.1. Overview
      • 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.11.3. Algeria Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.6.11.4. Algeria Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 10.6.11.5. Algeria Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.12. Egypt
      • 10.6.12.1. Overview
      • 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.12.3. Egypt Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.6.12.4. Egypt Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 10.6.12.5. Egypt Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.13. Rest of MEA
      • 10.6.13.1. Overview
      • 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.13.3. Rest of MEA Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.6.13.4. Rest of MEA Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 10.6.13.5. Rest of MEA Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)

11. Key Vendor Analysis- Frontotemporal Dementia Industry

  • 11.1. Competitive Benchmarking
    • 11.1.1. Competitive Dashboard
    • 11.1.2. Competitive Positioning
  • 11.2. Company Profiles
    • 11.2.1. Transposon Therapeutics
    • 11.2.2. AstraZeneca plc
    • 11.2.3. Alector Inc.
    • 11.2.4. Pfizer Inc.
    • 11.2.5. Denali Therapeutics Inc.
    • 11.2.6. Johnson & Johnson Services Inc.
    • 11.2.7. Prevail Therapeutics
    • 11.2.8. Wave Life Sciences
    • 11.2.9. GlaxoSmithKline plc
    • 11.2.10. TauRx Pharmaceuticals Ltd.
    • 11.2.11. Others

12. 360 Degree AnalystView

13. Appendix

  • 13.1. Research Methodology
  • 13.2. References
  • 13.3. Abbreviations
  • 13.4. Disclaimer
  • 13.5. Contact Us